In the hypoxia environment, the high expression of HIF-1 in glioma cells affects the increased expression of PD-L1, and the combination of HIF-1 inhibitor and PD-L1 inhibitor can significantly improve the efficacy (134). Here, SETD2 is linked to central nervous system cancer.